1.Erratum to: Corrigendum: 2023 Korean Society of Menopause -Osteoporosis Guidelines Part I
Dong Ock LEE ; Yeon Hee HONG ; Moon Kyoung CHO ; Young Sik CHOI ; Sungwook CHUN ; Youn-Jee CHUNG ; Seung Hwa HONG ; Kyu Ri HWANG ; Jinju KIM ; Hoon KIM ; Dong-Yun LEE ; Sa Ra LEE ; Hyun-Tae PARK ; Seok Kyo SEO ; Jung-Ho SHIN ; Jae Yen SONG ; Kyong Wook YI ; Haerin PAIK ; Ji Young LEE
Journal of Menopausal Medicine 2024;30(3):179-179
2.Erratum to: Corrigendum: 2023 Korean Society of Menopause -Osteoporosis Guidelines Part I
Dong Ock LEE ; Yeon Hee HONG ; Moon Kyoung CHO ; Young Sik CHOI ; Sungwook CHUN ; Youn-Jee CHUNG ; Seung Hwa HONG ; Kyu Ri HWANG ; Jinju KIM ; Hoon KIM ; Dong-Yun LEE ; Sa Ra LEE ; Hyun-Tae PARK ; Seok Kyo SEO ; Jung-Ho SHIN ; Jae Yen SONG ; Kyong Wook YI ; Haerin PAIK ; Ji Young LEE
Journal of Menopausal Medicine 2024;30(3):179-179
3.Erratum to: Corrigendum: 2023 Korean Society of Menopause -Osteoporosis Guidelines Part I
Dong Ock LEE ; Yeon Hee HONG ; Moon Kyoung CHO ; Young Sik CHOI ; Sungwook CHUN ; Youn-Jee CHUNG ; Seung Hwa HONG ; Kyu Ri HWANG ; Jinju KIM ; Hoon KIM ; Dong-Yun LEE ; Sa Ra LEE ; Hyun-Tae PARK ; Seok Kyo SEO ; Jung-Ho SHIN ; Jae Yen SONG ; Kyong Wook YI ; Haerin PAIK ; Ji Young LEE
Journal of Menopausal Medicine 2024;30(3):179-179
4.The 2024 Guidelines for Osteoporosis - Korean Society of Menopause
Dong Ock LEE ; Yeon Hee HONG ; Moon Kyoung CHO ; Young Sik CHOI ; Sungwook CHUN ; Youn-Jee CHUNG ; Seung Hwa HONG ; Kyu Ri HWANG ; Jinju KIM ; Hoon KIM ; Dong- Yun LEE ; Sa Ra LEE ; Hyun-Tae PARK ; Seok Kyo SEO ; Jung-Ho SHIN ; Jae Yen SONG ; Kyong Wook YI ; Haerin PAIK ; Ji Young LEE
Journal of Menopausal Medicine 2024;30(1):1-23
5.The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II
Dong Ock LEE ; Yeon Hee HONG ; Moon Kyoung CHO ; Young Sik CHOI ; Sungwook CHUN ; Youn-Jee CHUNG ; Seung Hwa HONG ; Kyu Ri HWANG ; Jinju KIM ; Hoon KIM ; Dong-Yun LEE ; Sa Ra LEE ; Hyun-Tae PARK ; Seok Kyo SEO ; Jung-Ho SHIN ; Jae Yen SONG ; Kyong Wook YI ; Haerin PAIK ; Ji Young LEE
Journal of Menopausal Medicine 2024;30(2):55-77
6.Corrigendum: 2023 Korean Society of Menopause - Osteoporosis Guidelines Part I
Dong Ock LEE ; Yeon Hee HONG ; Moon Kyoung CHO ; Young Sik CHOI ; Sungwook CHUN ; Youn-Jee CHUNG ; Seung Hwa HONG ; Kyu Ri HWANG ; Jinju KIM ; Hoon KIM ; Dong-Yun LEE ; Sa Ra LEE ; Hyun-Tae PARK ; Seok Kyo SEO ; Jung-Ho SHIN ; Jae Yen SONG ; Kyong Wook YI ; Haerin PAIK ; Ji Young LEE
Journal of Menopausal Medicine 2024;30(2):126-126
7. Immune enhancement effect of an herb complex extract through the activation of natural killer cells and the regulation of cytokine levels in a cyclophosphamide-induced immunosuppression rat model
Sung Min WOO ; Woo Rin CHOI ; Hae Lim KIM ; Kyung Hyeon KIM ; Joo Won SUH ; Dooly JANG ; Chun Sik YI ; Joo Won SUH ; Jong Tae KIM ; Won Hee CHOI ; Seung Hee JANG ; Min Jeung KIM ; Ji Hyang WEE ; Yeon Ki KIM ; Bao LE ; Seung Hwan YANG
Asian Pacific Journal of Tropical Medicine 2018;11(12):653-658
Objective: To investigate the effects of a herb complex extract (HCE) prepared from Cornus officinalis Sieb. Et Zucc., Eriobotrya japonica Lindley, and olive leaves on immune response of mouse spleen NK cells in vitro and in vivo analysis. Methods: The activity of natural killer (NK) cells was measured in splenocytes and YAC-1 cells. Mice were immunosuppressed using cyclophosphamide (5 mg/kg body weight). Three different doses of HCE (200, 400, and 800 mg/kg body weight) and red ginseng extract (800 mg/kg body weight) which was used as standard immunomodulatory herb were administered orally for 4 weeks. The body weight, dietary, water intake, organs (liver, thymus, and spleen) weight, completed blood count, and cytokines (tumor necrosis factor alpha, interferon gamma, and interleukin-2) production was measured. Results: At the maximum concentration of HCE, the activity of NK cells was increased by 48.5%. HCE increased liver, spleen, and thymus weights without altering numbers of white blood cells, lymphocytes, and neutrophils in a cyclophosphamide-induced immunosuppression rat model. However, HCE recovered the inhibited cytokine expression; HCE (800 mg/kg) increased cytokines levels. The results indicate the immune enhancement potential of this HCE. Conclusion: The HCE enhances immunity by increasing NK cell activity, regulating cytokine levels, and maintaining spleen weight. Therefore, it may be used as a potential immunity enhancer.
8.Surgical Techniques for Percutaneous Intramedullary Fixation with Steinmann Pins for Clavicle Shaft Fractures.
Sung Sik HA ; Jae Chun SIM ; Min Chul SUNG ; Jong Hyun JEON ; Yi Rak SEO
The Journal of the Korean Orthopaedic Association 2017;52(1):7-14
PURPOSE: To report the clinical results from surgical treatment for clavicle shaft fracture by percutaneous intramedullary fixation with Steinmann pins. MATERIALS AND METHODS: Between January 2004 and June 2014, the medical records of 135 patients who underwent percutaneous intramedullary fixation with Steinmann pins were reviewed. The mean follow-up periods were 15 months. The functional results were evaluated with The Disabilities of the Arm, Shoulder and Hand (DASH) score and Constant score. The clinical results were evaluated with the shortened length of the clavicle, length of surgical wound, operation time and Kang's criteria. RESULTS: The mean bone union period was 11.6 weeks (8–16 weeks). The mean DASH score was 11.8. The mean Constant score was 91.2. The mean shortened length of the clavicle was less than 20 mm. The mean length of surgical wound was 1.2 cm (0.7–1.5 cm). The mean operation time was 18 minutes (10–35 minutes). Using Kang's criteria, 131 out of 135 patients (97.0%) showed good results. Complications included were 3 pin migrations and 2 non-unions. CONCLUSION: Percutaneous intramedullary fixation with Steinmann pins showed good results for treating clavicle shaft fracture.
Arm
;
Clavicle*
;
Follow-Up Studies
;
Hand
;
Humans
;
Medical Records
;
Shoulder
;
Wounds and Injuries
9.Usefulness of Cardiac Biomarkers in the Evaluation of Prognosis and Cardiac Involvement in Patients with Acute Aortic Syndrome.
Jong Yoon KIM ; Kye Hun KIM ; Yi Rang YIM ; Jae Yeong CHO ; Doo Sun SIM ; Hyun Ju YOON ; Nam Sik YOON ; Young Joon HONG ; Hyung Wook PARK ; Ju Han KIM ; Youngkeun AHN ; Myung Ho JEONG ; Jeong Gwan CHO ; Jong Chun PARK
Journal of Lipid and Atherosclerosis 2016;5(1):27-36
OBJECTIVE: To investigate the usefulness of cardiac biomarkers in the evaluation of prognosis and cardiac involvement (CI) in patients with acute aortic syndrome (AAS). METHODS: A total of 260 AAS patients with the measurements of cardiac biomarkers were divided into 2 groups; the survived (n=215, 60.6±13.7 years, 110 males) vs the dead (n=45, 64.5±13.6 years, 19 males). N-terminal pro-B-type natriuretic peptide (NT-proBNP), cardiac specific troponin-I (cTnI), C-reactive protein (CRP), creatinine kinase (CK), MB fraction of CK (CK-MB), and D-dimer were compared. RESULTS: NT-proBNP and D-dimer were significantly elevated in the dead group than in the survived group (3558.7±5497.2 vs 949.9±2307.3 pg/mL, p<0.001, 4.5±5.1 vs 2.0±3.2 ug/mL, p<0.001, respectively). CI was observed in 59 patients (22.7%), and NT-proBNP was significantly elevated in patients with CI than in patients without CI (2497.7±4671.3 vs 722.5±1489.1 pg/mL, p=0.034). In univariate analysis, Stanford type A, CI, NT-proBNP, and D-dimer were significantly associated with mortality, but NT-proBNP was the only significant independent predictor of mortality in multivariate analysis. By receiver operating characteristic curve analysis, the optimal cut-off value to predict mortality was 517.0 pg/mL for NT-proBNP (area under the curve 0.797, sensitivity 86.7%, specificity 71.7%). CONCLUSION: The elevation of cardiac biomarkers is not infrequent in patients with AAS. NT-proBNP is significantly associated with CI and is an independent predictor of mortality in patients with AAS. The measurement of NT-proBNP would be useful in the risk stratification of AAS.
Biomarkers*
;
C-Reactive Protein
;
Creatinine
;
Humans
;
Mortality
;
Multivariate Analysis
;
Phosphotransferases
;
Prognosis*
;
ROC Curve
;
Sensitivity and Specificity
;
Troponin I
10.Predictors of the Development of Significant Tricuspid Regurgitation after Permanent Pacemaker Implantation.
Kyoung Jin LEE ; Kye Hun KIM ; Yi Rang YIM ; Hyuk Jin PARK ; Seung Hun LEE ; Ji Eun KIM ; Hyung Ki JEONG ; Hyun Ju YOON ; Nam Sik YOON ; Young Joon HONG ; Hyung Wook PARK ; Ju Han KIM ; Yongkeun AHN ; Myung Ho JEONG ; Jeong Gwan CHO ; Jong Chun PARK
Korean Journal of Medicine 2014;86(5):577-584
BACKGROUND/AIMS: We sought to identify predictors of significant tricuspid regurgitation (TR) after successful permanent pacemaker (PPM) implantation in Korean patients. METHODS: Of 404 patients who underwent PPM implantation, 187 patients who had both baseline and follow-up echocardiographic examinations were assigned to one of two groups: no development or change in TR (Group I, n = 172, 65.5 +/- 13.7 years) versus the development of significant TR (Group II, n = 15, 72.1 +/- 8.3 years). Clinical, laboratory, and echocardiographic variables were compared between the two groups. RESULTS: Overall, the grade of TR was significantly aggravated from 0.46 +/- 0.73 to 0.81 +/- 0.84 (p < 0.001) during 3.1 +/- 1.8 years of follow-up (0.49 +/- 0.75 to 0.69 +/- 0.74 in Group I, p < 0.001; 0.13 +/- 0.35 to 2.27 +/- 0.46 in Group II, p < 0.001). The de novo development or aggravation of TR was observed in 66 patients (35.3%), and significant TR developed in 15 patients (8.0%). The presence of atrial fibrillation (AF) was significantly higher (53.3 vs. 18.6%, p = 0.002), and the implantation of a ventricle pacing, ventricle sensing, inhibited by ventricular event (VVI) type pacemaker was more frequent in Group II than in Group I (46.7 vs. 15.1%, p = 0.002). Other variables were not different between the groups. CONCLUSIONS: The development or aggravation of TR was not rare after successful PPM implantation, even though the development of significant TR was uncommon. The presence of AF and the implantation of a VVI type pacemaker were predictors of the development of significant TR. Together, the results of this study suggest that the development or aggravation of TR should be monitored carefully after PPM implantation.
Atrial Fibrillation
;
Echocardiography
;
Follow-Up Studies
;
Humans
;
Tricuspid Valve Insufficiency*

Result Analysis
Print
Save
E-mail